LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis



Status:Recruiting
Conditions:Infectious Disease, Hematology
Therapuetic Areas:Hematology, Immunology / Infectious Diseases
Healthy:No
Age Range:Any - 18
Updated:5/6/2018
Start Date:July 2014
End Date:July 2023
Contact:Heidi M Clough, BSN
Email:Heidi.clough@stjude.org
Phone:901-595-0362

Use our guide to learn which trials are right for you!

The LCH-IV is an international, multicenter, prospective clinical study for pediatric
Langerhans Cell Histiocytosis LCH (age < 18 years).

The international efforts of the past 20 years have shown that combination therapy with
vinblastine and prednisone is an effective therapy for Multi-system (MS)-LCH. The previous
prospective trial LCH-III confirmed this regimen as a standard regimen for MS-LCH in patients
with and without risk organ involvement. It also showed that prolonged treatment in the
latter group (treatment duration of 12 vs. 6 months) is superior in preventing disease
reactivations. The results of this trial are encouraging and serve as a basis for the LCH-IV
study design.Due to the complexity of the disease presentations and outcomes, the LCH-IV
study seeks to tailor treatment based on features at presentation and on response to
treatment, leading to seven strata:

- Stratum I: First-line treatment for MS-LCH patients (Group 1) and patients with Single
system (SS)-LCH with multifocal bone or "Central Nervous System (CNS)-risk" lesions
(Group 2)

- Stratum II: Second-line treatment for non-risk patients (patients without risk organ
involvement who fail first-line therapy or have a reactivation after completion of
first-line therapy)

- Stratum III: Salvage treatment for risk LCH (patients with dysfunction of risk organs
who fail first-line therapy)

- Stratum IV: Stem cell transplantation for risk LCH (patients with dysfunction of risk
organs who fail first-line therapy)

- Stratum V: Monitoring and treatment of isolated tumorous and neurodegenerative CNS-LCH

- Stratum VI: Natural history and management of "other" SS-LCH (patients who do not need
systemic therapy at the time of diagnosis)

- Stratum VII: Long-term Follow up (all patients irrespective of previous therapy will be
followed for reactivation or permanent consequences once complete disease resolution has
been achieved and the respective protocol treatment completed)

Inclusion Criteria:

- Stratum I

- Patients must be less than 18 years of age at the time of diagnosis.

- Patients must have histological verification of the diagnosis of Langerhans cell
histiocytosis according to the criteria described in Section 6.1

- Signed informed consent form

- Stratum II

- Patients of Stratum I who have:

- Progressive disease (AD worse) in non-risk organs after 6 weeks (Initial Course

- AD intermediate or worse in non-risk organs or AD better in risk organs after 12
weeks (Initial Course 2)

- Disease progression (AD worse) in non-risk organs at any time during continuation
treatment

- Active disease at the end of Stratum I treatment

- Disease reactivation in non-risk organs at any time after completion of Stratum I
treatment

- Stratum III

- Patients from Stratum I who fulfill the following criteria:

- AD worse in risk organs after week 6 (after Initial Course 1), or AD worse or AD
intermediate in risk organs after week 12 (after Initial Course 2).

- Presence of unequivocally severe organ dysfunction at the above mentioned
evaluation points (hematological dysfunction, liver dysfunction, or both of them)
as

- Hb <70 g/L (<7.0 g/dl) and/or transfusion dependency

- PLT <20 x109/L (20,000/μL) and/or transfusion dependency (both criteria have
to be fulfilled) AND/OR

- Liver dysfunction (or digestive involvement with protein loss)

- Total protein <55 g/L or substitution dependency

- Albumin <25 g/L or substitution dependency (at least one of the two criteria
to be fulfilled)

- Stratum IV

- Patients from Stratum I or Stratum III who fulfill the following criteria:

- AD worse in risk organs after week 6 (after Initial Course 1), or AD worse or AD
intermediate in risk organs after week 12 (after Initial Course 2) of Stratum I
OR

- AD worse after the 2nd and 3rd 2-CdA/Ara-C course, and those AD worse or AD
intermediate after the 4th 2-CdA/Ara-C course of Stratum III AND

- Presence of unequivocally severe organ dysfunction at the above mentioned
evaluation points (hematological dysfunction, liver dysfunction, or both of them)
as defined in Table XI (see Section 10.3.1).

- Informed consent: All patients or their legal guardians (if the patient is <18
years of age) must sign an Ethics or institutional Review Board approved consent
form indicating their awareness of the investigational nature and the risks of
this study. When appropriate, younger patients will be included in all
discussions in order to obtain assent.

- Adequate organ function: Patients should have adequate hepatic, renal, cardiac
and pulmonary function to undergo reduced intensity HCT based upon local
institutional guidelines, or at a minimum meet requirements noted in eligibility
checklist Appendix A-VIII_1. However, significant hepatic and pulmonary
dysfunction, if secondary to underlying LCH disease activity, will not exclude
patients from protocol enrollment and should be discussed with the National PI
Coordinator and the Coordinating Principal Investigator.

- Stratum V

- All patients with verified diagnosis of LCH and MRI findings consistent with
ND-CNSLCH irrespective of previous treatments (also those not registered to other
Strata ofLCH-IV).

- Patients with isolated tumorous CNS-LCH (including isolated DI with mass lesion
in the hypothalamus-pituitary axis). In patients with already established
diagnosis of LCH and radiologic finding of CNS lesions compatible with LCH, a
biopsy of the lesion is not obligatory. In all other cases a biopsy of the lesion
is needed for inclusion into the study

- Stratum VI

-- Patients with newly diagnosed SS-LCH and localization other than "multifocal
bone",isolated tumorous CNS lesion, or isolated "CNS-risk" lesion.

- Stratum VII -- All patients registered in LCH IV (regardless of treatment) as long as
consent for longterm follow-up has not been withheld.

Exclusion Criteria:

- Stratum I

- Pregnancy (patients of child-bearing age must be appropriately tested before
chemotherapy)

- LCH-related permanent consequences (e.g. vertebra plana, sclerosing cholangitis,
lung fibrosis, etc.) in the absence of active disease

- Prior systemic therapy

- Stratum II

- Patients with progressive disease in risk organs

- Permanent consequences (e.g. sclerosing cholangitis, lung fibrosis, etc.) without
evidence of active LCH in the same organ or in any other locations

- No written consent of the patient or his/her parents or legal guardian

- Stratum III

- The presence of any of the following criteria will exclude the patient from the
study:

- Isolated sclerosing cholangitis without evidence of active hepatic LCH as the
only evidence of risk organ involvement.

- Inadequate renal function as defined by serum creatinine > 3x normal for age

- Stratum IV

- Pulmonary failure (requiring mechanical ventilation) not due to active LCH.

- Isolated liver sclerosis or pulmonary fibrosis, without active LCH.

- Uncontrolled active life-threatening infection.

- Decreased renal function with a GFR of less than 50ml/1.73m2/min.

- Pregnancy or active breast feeding

- Failure to provide signed informed consent

- Stratum VI

- Patients with SS-LCH who have an isolated tumorous CNS lesion (they are eligible
for Stratum V),

- Patients with isolated "CNS-risk" or multifocal bone lesions (they are eligible
for Stratum I, Group 2)
We found this trial at
19
sites
30 Prospect Ave
Hackensack, New Jersey 07601
(201) 996-2000
Hackensack University Medical Center Hackensack University Medical Center, part of the Hackensack University Health Network,...
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
3400 N Charles St
Baltimore, Maryland 21205
410-516-8000
Phone: 410-955-0432
Johns Hopkins University The Johns Hopkins University opened in 1876, with the inauguration of its...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
Principal Investigator: Mary Huang, MD
Phone: 617-726-2737
?
mi
from
Boston, MA
Click here to add this to my saved trials
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
 1-513-636-4200 
Phone: 513-636-1773
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
282 Washington St
Hartford, Connecticut 06106
(860) 545-9000
Principal Investigator: Andrea Orsey, MD
Connecticut Children's Medical Center Connecticut Children’s Medical Center is a nationally recognized, 187-bed not-for-profit children’s...
?
mi
from
Hartford, CT
Click here to add this to my saved trials
4650 Sunset Blvd
Los Angeles, California 90027
 (323) 660-2450
Principal Investigator: Rima Jubran, MD
Childrens Hospital Los Angeles Children's Hospital Los Angeles is a 501(c)(3) nonprofit hospital for pediatric...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
262 Danny Thomas Pl
Memphis, Tennessee 38105
(901) 495-3300
Principal Investigator: Patrick Campbell, MD
St. Jude Children's Research Hospital St. Jude is unlike any other pediatric treatment and research...
?
mi
from
Memphis, TN
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Barbara Degar, MD
Phone: 617-632-6801
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Charleston, South Carolina 29425
Principal Investigator: Jacqueline Kraveka, DO
Phone: 843-792-2957
?
mi
from
Charleston, SC
Click here to add this to my saved trials
1 Children's Way
Little Rock, Arkansas 72202
(501) 364-1100
Principal Investigator: Kimo Stine, MD
Arkansas Children's Hospital Arkansas Children's Hospital (ACH) is the only pediatric medical center in Arkansas...
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
Madera, California 93636
Principal Investigator: David Samuel, MD
Phone: 559-353-5480
?
mi
from
Madera, CA
Click here to add this to my saved trials
Minneapolis, Minnesota 55404
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
New Hyde Park, New York 11040
?
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
1919 E Thomas Rd
Phoenix, Arizona 85006
(602) 933-1000
Principal Investigator: Michael Henry, MD
Phoenix Children's Hospital Phoenix Children's Hospital has provided hope, healing, and the best healthcare for...
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
?
mi
from
Spokane, WA
Click here to add this to my saved trials
475 Seaview Ave
Staten Island, New York 10305
(718) 226-9000
Principal Investigator: Sarah Vaiselbuh`, MD
Phone: 718-226-6435
Staten Island University Hospital Staten Island University Hospital is a 714-bed, specialized teaching hospital located...
?
mi
from
Staten Island, NY
Click here to add this to my saved trials
750 East Adams Street
Syracuse, New York 13210
?
mi
from
Syracuse, NY
Click here to add this to my saved trials
111 Michigan Ave NW
Washington, District of Columbia
(202) 476-5000
Childrens National Medical Center As the nation’s children’s hospital, the mission of Children’s National Medical...
?
mi
from
Washington,
Click here to add this to my saved trials